Figure 3.
MC and impending or established secondary GF stratified based on CXCL9 levels. (A) Grouped plasma proteomic expression in patients with and without intervention-free sustained engraftment. Five analytes were identified to be statistically significant (maximum false discovery proportion of 0.1 at an 80% confidence level). (B) Cumulative incidence of secondary GF, impending or established, stratified by median D+14 CXCL9 level, 2394 pg/mL. (C) Cumulative incidence of secondary GF, impending or established, stratified based on median D+28 CXCL9 level, 2867 pg/mL. D+14, day +14 after HCT; D+28, day +28 after HCT.

MC and impending or established secondary GF stratified based on CXCL9 levels. (A) Grouped plasma proteomic expression in patients with and without intervention-free sustained engraftment. Five analytes were identified to be statistically significant (maximum false discovery proportion of 0.1 at an 80% confidence level). (B) Cumulative incidence of secondary GF, impending or established, stratified by median D+14 CXCL9 level, 2394 pg/mL. (C) Cumulative incidence of secondary GF, impending or established, stratified based on median D+28 CXCL9 level, 2867 pg/mL. D+14, day +14 after HCT; D+28, day +28 after HCT.

Close Modal

or Create an Account

Close Modal
Close Modal